Login / Register Order My Items
Contact Us
800.227.0627
Contact Us Quote Order Login / Register
protein–oligonucleotide conjugates • nanobody delivery • targeted RNA therapeutics

Nanobody–Oligonucleotide Conjugates

Targeted siRNA, ASO, SSO, PMO, morpholino, and related oligonucleotide payloads designed for precision delivery, molecular targeting, and advanced research applications.

Nanobody–oligonucleotide conjugates combine the target-selective recognition of single-domain antibody fragments with programmable DNA or RNA payloads for targeted delivery, receptor-directed gene silencing, molecular imaging, and advanced research workflows.

siRNA ASO SSO PMO Morpholino Site-specific conjugation Protein–oligo platform
Request a quote Browse payloads
Talk to a chemist Request a quote
Overview Payloads Why nanobodies Structure Conjugation chemistry Targeting applications Architecture Target examples Nanobody vs antibody Related services FAQ Contact

Overview

Nanobody–oligonucleotide conjugates are a specialized class of protein–oligonucleotide conjugates in which a nanobody is linked to an oligonucleotide payload such as siRNA, antisense oligonucleotides (ASO), splice-switching oligonucleotides (SSO), PMO, morpholino, and related RNA therapeutic formats. These constructs combine target-specific recognition with the programmable function of nucleic acid therapeutics and have emerged as promising architectures for targeted RNA delivery, receptor-mediated uptake, and molecular imaging [1].

Because nanobodies are substantially smaller than full-length antibodies (~15 kDa vs ~150 kDa), they can offer improved tissue penetration, simplified recombinant engineering, and more controlled conjugation strategies compared with conventional antibody–oligonucleotide conjugates [2].

In the literature, these constructs are also described as nanobody–siRNA conjugates or nanobody-mediated RNA delivery systems.

We support custom nanobody–oligonucleotide conjugation with project-dependent linker and payload design, including site-specific and bioorthogonal strategies for protein–RNA and protein–DNA conjugate architectures.

Platform highlights
Targeted payload delivery

Nanobody recognition domains can direct oligonucleotide payloads to defined receptors or cell populations.

Flexible payload scope

Supports siRNA, ASO, SSO, PMO, morpholino, miRNA-related oligos, aptamers, and selected guide-RNA style constructs.

Site-specific chemistry

Compatible with maleimide-thiol, click chemistry, NHS coupling, and other controlled protein–oligonucleotide linker strategies.

From Llama-Derived Nanobody to Final Oligonucleotide Conjugate
Workflow showing llama immunization, nanobody generation, purification, and final nanobody–oligonucleotide conjugate product
Representative workflow showing llama immunization, nanobody discovery and purification, followed by construction of the final nanobody–oligonucleotide conjugate for siRNA, ASO, SSO, PMO, and related payload formats.
Important distinction: nanobody–oligonucleotide conjugates belong under protein–oligonucleotide conjugates, not small-molecule oligo conjugates.

Nanobody–Oligonucleotide Conjugate Architecture

A nanobody–oligonucleotide conjugate is typically organized as a target-binding nanobody, a defined linker or conjugation handle, and an oligonucleotide payload. The exact architecture depends on whether the project prioritizes receptor targeting, intracellular release, splice modulation, imaging, or analytical detection.

1. Nanobody targeting domain

Provides receptor or antigen recognition and determines the biological entry point for the conjugate.

2. Linker / conjugation module

Controls orientation, spacing, cleavability, and the degree of site specificity in the final construct.

3. Oligonucleotide payload

Can be siRNA, ASO, SSO, PMO, morpholino, or other nucleic acid formats depending on the intended mechanism.

Design objective: the best architecture balances target binding, conjugate stability, payload function, and downstream cellular trafficking.

Supported Oligonucleotide Payloads

Payload Typical role Why pair with nanobody Common design considerations
siRNA Gene silencing Targeted uptake and receptor-directed delivery Strand selection, linker placement, endosomal trafficking, and release strategy.
ASO RNase H or steric modulation Targeted engagement of specific cell populations Backbone chemistry, serum stability, and steric impact of conjugation.
SSO Splice correction Delivery to splice-relevant tissues or cell types Cell entry, nuclear access, and linker cleavability.
PMO / Morpholino Steric splice modulation Targeted uptake for otherwise hard-to-deliver neutral oligos Conjugation handle availability, stoichiometry, and trafficking profile.
miRNA-related oligos Mimics or inhibitors Cell-specific modulation of regulatory pathways Payload stability, duplex stability and strand handling, and potency retention.
Aptamer / guide-like constructs Research or binding applications Specialized targeting, imaging, or assay development Functional folding, linker orientation, and assay-specific optimization.

Why Use Nanobodies for Oligo Conjugation

Nanobodies are attractive targeting domains for oligonucleotide conjugation because they combine high target specificity, compact size, recombinant accessibility, and modular engineering flexibility. In many delivery and imaging workflows, these properties can simplify conjugate architecture while preserving strong target recognition.

Smaller size

Nanobodies are far smaller than full antibodies, which can support better tissue penetration and reduce steric burden in conjugate design.

Recombinant accessibility

Recombinant production can simplify engineering of site-specific handles and controlled conjugation positions.

Targeted recognition

Nanobody binding can bias delivery toward defined receptors, tumor markers, or disease-relevant cell populations.

Practical value: nanobody–oligonucleotide conjugates are especially attractive when the goal is to reduce overall conjugate size while maintaining protein-based targeting and enabling more controlled protein–oligo buildouts.

Structural Characteristics of Nanobodies

Nanobodies are single-domain antibody fragments derived from heavy-chain-only antibody systems. Their compact structure is one of the main reasons they are useful in oligonucleotide conjugation, especially when a smaller targeting scaffold is preferred over a full immunoglobulin.

Characteristic Why it matters in oligo conjugation
Single-domain format Eliminates heavy/light chain pairing and supports compact targeting architectures.
Small molecular size Can improve tissue access and reduce steric interference around the oligonucleotide payload.
Recombinant engineerability Facilitates introduction of site-specific cysteine or click-compatible handles for controlled conjugation.
High solubility and stability Useful for maintaining protein integrity during conjugation, purification, and downstream assay handling.
Defined orientation potential Supports more deliberate positioning of linker and oligonucleotide payload relative to the binding domain.
Design implication: the structural simplicity of nanobodies often makes them easier to adapt to site-specific oligo conjugation strategies than larger full-antibody formats.

Conjugation Chemistry & Linker Engineering

Chemistry choice affects stoichiometry, orientation, activity retention, and manufacturability.

Common chemistries
  • Maleimide–thiol coupling
  • NHS–amine coupling
  • Azide–alkyne click chemistry
  • DBCO-based copper-free click chemistry
  • Engineered site-specific linker strategies
Design priorities
  • Defined nanobody-to-oligo ratio
  • Preservation of target binding
  • Retention of oligo function and stability
  • Cleavable vs non-cleavable linker choice
  • Analytical confirmation of conjugate integrity
Chemistry Typical use Why it matters
Maleimide–thiol Cysteine-directed protein conjugation Popular when nanobody engineering provides a defined thiol handle for controlled attachment.
NHS–amine General amine-reactive coupling Simple and flexible, but often less site-specific than engineered strategies.
Azide–alkyne click Bioorthogonal conjugation Supports modular and highly selective coupling between protein and oligo components.
DBCO / SPAAC Copper-free click coupling Useful when copper avoidance is preferred for payload or protein compatibility.

Targeting Applications

Precision oncology

Tumor-associated receptors and antigens can be explored for targeted nanobody–siRNA or nanobody–ASO delivery studies.

Cell-type selective research

Nanobody recognition enables receptor-directed uptake studies and mechanistic investigation of targeted nucleic acid delivery.

Imaging & detection

Nanobody–oligo architectures can also support molecular imaging, barcoding, and probe-based assay development.

Representative target classes: EGFR, HER2, CD71, PD-L1, VEGF-related systems, and other receptor or antigen targets depending on project design.

Representative Nanobody Target Examples

The examples below illustrate common target classes researchers may consider when designing nanobody-mediated oligonucleotide delivery or probe systems.

Target Target class Potential payload fit Why it may be useful
EGFR Cell-surface receptor siRNA, ASO, imaging probes Relevant for receptor-directed oncology workflows and targeted uptake studies.
HER2 Oncology receptor target siRNA, ASO, barcoding constructs Useful when receptor-selective targeting or tumor-associated delivery is a design priority.
CD71 Transferrin receptor siRNA, ASO, PMO Frequently discussed in delivery concepts where receptor-mediated uptake is desired.
PD-L1 Immune checkpoint target ASO, imaging, mechanistic probes Can support precision immuno-oncology and receptor-specific probe development.
VEGF-related targets Soluble / receptor-associated signaling targets Imaging probes, research oligos Useful in angiogenesis-focused research and targeted assay design.
Important note: target selection should be driven by target biology, internalization behavior, tissue distribution, and compatibility with the intended oligonucleotide mechanism.

Nanobody vs Antibody Oligonucleotide Conjugates

Both nanobody–oligonucleotide and antibody–oligonucleotide conjugates can provide targeted recognition, but they are not interchangeable. The best choice depends on payload, target biology, desired tissue penetration, and how much control is needed over conjugation architecture.

Feature Nanobody–Oligonucleotide Antibody–Oligonucleotide
Approximate size Much smaller single-domain format Full immunoglobulin format
Tissue penetration Often more favorable because of smaller size Can be more limited by overall molecular bulk
Recombinant engineering Often easier to engineer with site-specific handles More complex full-antibody architecture
Conjugation control Potentially more defined and compact Can be more heterogeneous depending on strategy
Payload steric burden Usually lower due to smaller targeting scaffold Usually higher because of antibody size and complexity
Use case Compact targeted delivery and research formats Established targeted conjugate platforms and diagnostics
Rule of thumb: choose nanobody–oligonucleotide conjugates when compact size, penetration, and controlled architecture are priorities; choose antibody–oligonucleotide conjugates when a conventional full-antibody targeting platform is preferred.

FAQ

Which oligonucleotide payloads can be conjugated to nanobodies?

Common payloads include siRNA, antisense oligonucleotides (ASO), splice-switching oligonucleotides (SSO), phosphorodiamidate morpholino oligonucleotides (PMO), miRNA-related oligonucleotides, aptamers, and selected guide RNA constructs depending on design goals.

Why use nanobodies instead of full antibodies for oligonucleotide conjugation?

Nanobodies are much smaller than full antibodies, which can improve tissue penetration, simplify recombinant production, and enable more controlled conjugation strategies while preserving target-specific recognition.

What conjugation chemistries are commonly used for nanobody–oligonucleotide conjugates?

Common strategies include maleimide-thiol coupling, NHS-amine coupling, azide-alkyne click chemistry, DBCO-based copper-free click chemistry, and other site-specific linker strategies depending on the nanobody and oligonucleotide design.

What are nanobody–oligonucleotide conjugates used for?

These conjugates are used for targeted gene silencing, receptor-directed delivery, molecular imaging, diagnostic research, and precision oncology or cell-targeting studies.

Can nanobodies be conjugated to siRNA, ASO, SSO, or PMO payloads?

Yes. Nanobodies can be conjugated to siRNA, antisense oligonucleotides (ASO), splice-switching oligonucleotides (SSO), PMO, morpholino payloads, and other nucleic acid constructs when the chemistry and architecture are matched to the project goal.

What is a nanobody–oligonucleotide conjugate?

A nanobody–oligonucleotide conjugate is a construct in which a single-domain antibody fragment is covalently linked to an oligonucleotide payload such as siRNA, ASO, SSO, or PMO for targeted delivery, detection, or research use.

What factors matter most when designing a nanobody–oligonucleotide conjugate?

Key design factors include target selection, nanobody orientation, conjugation site, linker chemistry, cleavable versus non-cleavable design, payload modality, stoichiometry, and the desired balance between stability and intracellular function.

Are nanobody–oligonucleotide conjugates mainly used for delivery or for research tools?

They can be used for both. Some designs focus on targeted delivery of therapeutic oligonucleotides, while others are built for imaging, barcoding, receptor-binding studies, analytical assays, or mechanistic research workflows.

More FAQ'sAll FAQ's

Contact & Project Scoping

For the fastest review, share the nanobody target, payload modality, desired conjugation chemistry, preferred attachment site, stoichiometry goals, and whether the project is intended for targeted delivery, imaging, or assay development.

Typical project inputs
  • Nanobody identity and target receptor / antigen
  • Payload: siRNA / ASO / SSO / PMO / morpholino / other
  • Conjugation handle availability
  • Cleavable vs non-cleavable linker preference
Priority workflows

Common requests include receptor-targeted siRNA delivery, nanobody–ASO research constructs, splice-modulating nanobody–PMO designs, and site-specific protein–oligonucleotide conjugation development.

Request a Quote Protein–oligonucleotide overview

Recommended reading

Key publications discussing nanobody engineering, antibody–oligonucleotide conjugates, and targeted nucleic acid delivery strategies.

  • Muyldermans S. Nanobodies: natural single-domain antibodies. Annual Review of Biochemistry. 2013.
  • De Vlieger D., et al. Single-domain antibodies and their therapeutic potential. Antibodies. 2019.
  • Rader C. Antibody–oligonucleotide conjugates for targeted delivery. Bioconjugate Chemistry.
  • Sugo T. et al. Antibody-mediated oligonucleotide delivery strategies. Nature Biotechnology.
  • Crooke S. Antisense drug discovery and delivery technologies. Nature Reviews Drug Discovery.

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.

Greetings Researchers,

Please be advised that any information, guidelines, writeups, and oral/video/graphic content on our website are intended solely as general guidelines.
It is the researcher's sole responsibility to conduct thorough research on the designs of the products intended for their experiments before submitting
their designs to Biosynthesis for review of production feasibility.
Thank you for your understanding.

Quick Links